REG - Hutchmed China Ltd - AGM held on May 13, 2025 – Poll Results

HUTCHMED (China)Announcement

Yesterday 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250513:nRSM4724Ia&default-theme=true

RNS Number : 4724I  Hutchmed (China) Limited  13 May 2025

 

Annual General Meeting held on May 13, 2025 - Poll Results

 

 

Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 13, 2025: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the "Company")
(Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and
special resolution put to its Annual General Meeting ("AGM") held on May 13,
2025 were duly passed. The poll results of the resolutions were as follows:

 

 

                                                                                              Number of Votes (%)*

                                                                                                                                  Passed by Shareholders

 Ordinary Resolutions

              For                                                                             Against      Withheld(#)

 1.           To consider and adopt the audited Financial Statements, and the Reports of the  493,635,784  67,770        54,915   Yes
              Directors and the Independent Auditors for the year ended December 31, 2024.

                                                                               (99.9863%)   (0.0137%)

 2(A).        To re-elect Dr Dan ELDAR as a Director.                                         479,808,571  13,910,941    38,955   Yes

                                                                                              (97.1824%)   (2.8176%)

 2(B).        To re-elect Dr Weiguo SU as a Director.                                         481,283,821  12,438,811    35,835   Yes

                                                                                              (97.4806%)   (2.5194%)

 2(C).        To re-elect Mr CHENG Chig Fung, Johnny as a Director.                           481,167,431  12,555,206    35,830   Yes

                                                                                              (97.4570%)   (2.5430%)

 2(D).        To re-elect Ms Edith SHIH as a Director.                                        466,597,573  27,124,459    35,935   Yes

                                                                                              (94.5061%)   (5.4939%)

 2(E).        To re-elect Ms Ling YANG as a Director.                                         484,362,585  9,360,052     35,830   Yes

                                                                                              (98.1042%)   (1.8958%)

 2(F).        To re-elect Dr Renu BHATIA as a Director.                                       493,441,294  281,240       35,935   Yes

                                                                                              (99.9430%)   (0.0570%)

 2(G).        To re-elect Dr Chaohong HU as a Director.                                       493,441,904  280,740       35,825   Yes

                                                                                              (99.9431%)   (0.0569%)

 2(H).        To re-elect Professor MOK Shu Kam, Tony as a Director.                          492,694,533  1,028,006     35,930   Yes

                                                                                              (99.7918%)   (0.2082%)

 2(I).        To re-elect Mr WONG Tak Wai as a Director.                                      493,633,871  88,768        35,830   Yes

                                                                                              (99.9820%)   (0.0180%)

 3.           To re-appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP  492,729,314  985,390       43,765   Yes
              as the Auditors of the Company for Hong Kong financial reporting and US

              financial reporting purposes, respectively, and to authorize the Directors to   (99.8004%)   (0.1996%)
              fix the Auditors' remuneration.

 Special Resolution
 4.           To grant a general mandate to the Directors to issue additional shares of the   493,550,312  179,327       28,830   Yes

            Company.^

                                                                               (99.9637%)   (0.0363%)

 Ordinary Resolution
 5.           To grant a general mandate to the Directors to repurchase shares of the         493,321,158  405,036       32,275   Yes
              Company.^

                                                                               (99.9180%)   (0.0820%)

 

*  Percentages rounded to 4 decimal places.

(#) A vote withheld is not a vote in law and is not counted in the calculation
of the proportion of the votes for or against a resolution.

^ The full text of Resolutions 4 and 5 are set out in the notice of AGM dated
April 8, 2025.

 

Notes:

 

(1)       All directors of the Company, namely Dr Dan ELDAR, Dr Weiguo
SU, Mr CHENG Chig Fung, Johnny, Ms Edith SHIH, Ms Ling YANG, Mr Paul
Rutherford CARTER, Dr Renu BHATIA, Dr Chaohong HU, Mr Graeme Allan JACK,
Professor MOK Shu Kam, Tony and Mr WONG Tak Wai, attended the AGM, either in
person or by means of electronic facilities.

 

(2)       Number of shares entitling the holders to attend and vote on
the resolution at the AGM: 871,601,095 shares.

 

(3)       Number of shares entitling the holders to attend and abstain
from voting in favor as set out in Rule 13.40 of the Rules Governing the
Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing
Rules") at the AGM: Nil.

 

(4)       Number of shares for holders required under the Listing Rules
to abstain from voting at the AGM: Nil.

 

(5)       The scrutineer for the poll at the AGM was Computershare
Investor Services (Jersey) Limited, the Principal Share Registrar of the
Company.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. Іt is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, and the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

CONTACTS

 

 Investor Enquiries                                   +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                     +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                      (mailto:HUTCHMED@fticonsulting.com)
 Ben Atwell / Alex Shaw                                   +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
 Brunswick - Zhou Yi                                  +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                      (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                      Nominated Advisor and Joint Broker
 Atholl Tweedie / Freddy Crossley / Rupert Dearden    +44 20 7886 2500

 HSBC                                                 Joint Broker
 Simon Alexander / Alina Vaskina / Arnav Kapoor       +44 20 7991 8888

 Cavendish                                            Joint Broker
 Geoff Nash / Nigel Birks                             +44 20 7220 0500

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGZZGMKGFGGKZM